Effect of Dehydroepiandrosterone (DHEA) on Hot Flashes in Postmenopausal Women

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the study is to evaluate the effect of daily oral intake of DHEA 50 mg for 4 months on reducing vasomotor symptoms (hot flashes) compared to placebo administration in postmenopausal women.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Québec, CHU de Québec; CHU de Quebec-Universite Laval
• Treatments: Dehydroepiandrosterone

Criteria

Inclusion Criteria:

• Healthy postmenopausal women with 50 or more moderate to severe hot flushes.

• Women between 40 to 70 years of age.

Exclusion Criteria:

• Body mass index (BMI) of 35 kg/m2 or more.

• Significant metabolic and endocrine diseases.

• Diagnosis of cancer.

• Use of steroids or drugs that interfere with the metabolism of estrogen.

• Use of any systemic estrogen, progestin, or DHEA in the eight weeks prior to randomization.

• Use of alternative therapies or natural products to treat postmenopausal symptoms in the four weeks prior to randomization.

• Palpable fibroids or uterine prolapse: Grade 2 or 3.

• Cigarette smoking